Comparison

KFE PTA vs CRUSE Control Urticaria

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

KFE PTA

Features
Read full description

Bezpłatna aplikacja mobilna KFE PTA, stanowiąca podręczny przewodnik uczestnika VIII Klinicznego Forum Ekspertów Polskiego Towarzystwa Alergologicznego w Warszawie. Zawiera szereg niezbędnych informacji organizacyjnych dotyczących lokalizacji, możliwości zakwaterowania i dojazdu. Pozwala m.in. na bieżąca aktualizację programu i ułożenie swojej indywidualnej agendy.

About

CRUSE Control Urticaria

This app helps individuals manage chronic urticaria by tracking daily symptoms and their impact on quality of life. It facilitates communication with healthcare providers to optimize treatment based on recorded data. Developed by leading dermatologists and allergologists, it aims to provide better control over the condition.

Highlights
  • Daily symptom recording
  • Quality of life impact tracking
  • Treatment response monitoring
  • Physician collaboration tool
  • Developed by medical experts
Features
Read full description

CRUSE® is an APP developed by renowned dermatologists and allergoligists to help patients with Chronic Urticaria manage their condition. Take control of your Chronic Urticaria by recording your symptoms and impact on your quality of life in just a few minutes each day. Track how you respond to treatment and how it can be improved by using CRUSE in cooperation with your treating physician. Over 50 million people worldwide have Chronic Urticaria. It is a common condition that causes itchy wheals and/or swellings (angioedema) and can be very debilitating. To ensure optimal treatment, continuous monitoring and documentation of disease activity is essential. From now on, CRUSE® will take care of this for you. Your UCARE Team - With more than 130 member centres in 41 countries, GA²LEN’s Urticaria Centres of Reference and Excellence (UCARE network) is the biggest and most active consortium of urticariologists and urticaria centres. Are you a physician? Find out more on www.cruse-control-com

Screenshots

KFE PTA1 screens
CRUSE Control Urticaria3 screens

Verdict

The call

The clearest difference is update cadence: CRUSE Control Urticaria at weekly against KFE PTA's every 9 months. On price, ads, in-app purchases and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

UpkeepUpdate frequency

KFE PTA ships an update every 9 months, CRUSE Control Urticaria weekly. The most recent releases landed on October 25, 2026 and October 30, 2026 respectively.

Scorecard1 real difference · 9 level
KFE PTA versus CRUSE Control Urticaria: the parameters behind the verdict, then further details
ParameterKFE PTACRUSE Control Urticaria
PriceFreeFree
Rating—4.8 (8 ratings) — better
Positive reviews—75.9% of reviews
Number of ratings—8 — better
Update frequencyEvery 9 monthsWeekly — better
AdsNoNo
In-app purchasesNoNo
Monetization—Free
DevicesiPhone, iPodiPhone, iPod
Requires iOS15.0 — better15.5
Further details — not scored
Size12 MB35 MB
Age rating17+17+
DeveloperAltaSoftMoxie GmbH

In-app purchases

None

KFE PTA

No in-app purchases

None

CRUSE Control Urticaria

No in-app purchases

Questions

Is KFE PTA free?
KFE PTA is free to download, with no in-app purchases.
Is CRUSE Control Urticaria free?
CRUSE Control Urticaria is free to download, with no in-app purchases.
Do KFE PTA or CRUSE Control Urticaria have ads?
Neither KFE PTA nor CRUSE Control Urticaria shows ads.
Which is updated more often, KFE PTA or CRUSE Control Urticaria?
KFE PTA ships an update every 9 months, and CRUSE Control Urticaria weekly. Most recently, KFE PTA was updated on October 25, 2026 and CRUSE Control Urticaria on October 30, 2026.

Other comparisons